bone-forming cell

Bone Therapeutics' core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

These conditions spur the proliferation of bone-forming cells. OSA also has been associated with fractures in which no internal repair was performed.

The external (periosteal) and internal (endocostal) bone surfaces are lined with bone-forming cells that form the periosteum and endosteum.

The product is a fully humanised monoclonal antibody that inhibits sclerostin, a protein which inhibits the activity of bone-forming cells. BPS-804 for OI has also previously been accepted into the EMA's Adaptive Pathways Programme and has been granted orphan drug status in both the US and EU.

Osteoclasts are bone specific cells originated from hematopoietic lineage that reabsorb bone matrix, so in correlation with osteoblasts, as bone-forming cells, remodel the bone.

A unique feature of stem cells isolated from the dental pulp of deciduous teeth is their capability of in vivo osteoinduction and recruitment of bone-forming cells, and bone tissue formation [24- 27].

(the companies partnered in late 2014 to expand Stryker's biologics portfolio), is a viable bone matrix containing endogenous bone-forming cells designed to facilitate bone repair and regeneration.

The integrity of the skeleton as well as the osseous integration of intercortical metal implants (e.g., total joint arthroplasty) requires the regulated activity of bone-forming cells (osteoblasts) and bone-resorbing cells (OC).

Fibrous dysplasia is a non inherited skeletal disorder in which bone-forming cells fail to mature and produce too much fibrous or connective tissue.